HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waiboci, L. W. Articles by Johnson, H. M. Search for Related Content PubMed PubMed Citation Articles by Waiboci, L. W. Articles by Johnson, H. M.

Both the Suppressor of Cytokine Signaling 1 (SOCS-1) Kinase Inhibitory Region and SOCS-1 Mimetic Bind to JAK2 Autophosphorylation Site: Implications for the Development of a SOCS-1 Antagonist¹

Department of Microbiology and Cell Science, University of Florida, Gainesville, FL 32611

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Suppressor of cytokine signaling (SOCS)-1 protein modulates signaling by IFN- by binding to the autophosphorylation site of JAK2 and by targeting bound JAK2 to the proteosome for degradation. We have developed a small tyrosine kinase inhibitor peptide (Tkip) that is a SOCS-1 mimetic. Tkip is compared in this study with the kinase inhibitory region (KIR) of SOCS-1 for JAK2 recognition, inhibition of kinase activity, and regulation of IFN--induced biological activity. Tkip and a peptide corresponding to the KIR of SOCS-1, ⁽⁵³⁾DTHFRTFRSHSDYRRI⁽⁶⁸⁾ (SOCS1-KIR), both bound similarly to the autophosphorylation site of JAK2, JAK2(1001–1013). The peptides also bound to JAK2 peptide phosphorylated at Tyr¹⁰⁰⁷, pJAK2(1001–1013). Dose-response competitions suggest that Tkip and SOCS1-KIR similarly recognize the autophosphorylation site of JAK2, but probably not precisely the same way. Although Tkip inhibited JAK2 autophosphorylation as well as IFN--induced STAT1- phosphorylation, SOCS1-KIR, like SOCS-1, did not inhibit JAK2 autophosphorylation but inhibited STAT1- activation. Both Tkip and SOCS1-KIR inhibited IFN- activation of Raw 264.7 murine macrophages and inhibited Ag-specific splenocyte proliferation. The fact that SOCS1-KIR binds to pJAK2(1001–1013) suggests that the JAK2 peptide could function as an antagonist of SOCS-1. Thus, pJAK2(1001–1013) enhanced suboptimal IFN- activity, blocked SOCS-1-induced inhibition of STAT3 phosphorylation in IL-6-treated cells, enhanced IFN- activation site promoter activity, and enhanced Ag-specific proliferation. Furthermore, SOCS-1 competed with SOCS1-KIR for pJAK2(1001–1013). Thus, the KIR region of SOCS-1 binds directly to the autophosphorylation site of JAK2 and a peptide corresponding to this site can function as an antagonist of SOCS-1.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The JAKs are a small but indispensable enzyme family that mediate the biological effects of cytokines, hormones, and growth factors by tyrosine phosphorylation of STATs (reviewed in Refs. 1 and 2). The IFNs, including types I and type II, hormones such as growth hormone and angiotensin, and growth factors such as thrombopoietin, are all dependent on JAK tyrosine phosphorylation of appropriate STAT transcription factors for their physiological functions (3, 4).

The immediate early signal transduction events associated with IFN- and its receptor subunits involve the obligatory action of two tyrosine kinases, JAK1 and JAK2 (reviewed in Ref. 5). The IFN- receptor (IFNGR)⁵ system is a heterodimeric complex consisting of an -subunit, IFNGR-1, and a -subunit, IFNGR-2, both of which are essential for the biological activity of IFN- (5). JAK1 is associated with the IFNGR-1 chain, whereas JAK2 is associated with the IFNGR-2 chain. The interaction of IFN-, primarily with the IFNGR-1 subunit, initiates a sequence of events that results in increased binding of JAK2 to IFNGR-1. This has important consequences for subsequent critical phosphorylation events. JAK2, in the process of binding to IFNGR-1, undergoes autophosphorylation, and at the same time IFNGR-1 is phosphorylated. These events occur in concert with JAK1 function, resulting in recruitment and tyrosine phosphorylation of the IFN- transcription factor, STAT1 (Ref. 5 ; reviewed in Ref. 6).

A family of proteins called suppressors of cytokine signaling (SOCS) negatively regulates JAK/STAT signaling (7, 8, 9). These inducible proteins share domains of homology that characterize the SOCS family. SOCS proteins are also negative regulators of signaling by other cytokines, growth factors, and hormones (reviewed in Refs. 10, 11, 12). There are currently eight identified members of the SOCS family, SOCS-1 to SOCS-7 and cytokine-inducible SH2 protein. SOCS-1 is of particular interest, because it is a negative regulator of JAK2 as well as several other cytokines and hormone receptor systems, including epidermal growth factor receptor (EGFR) (reviewed in Ref. 13).

Our laboratory recently designed a short 12-mer peptide, WLVFFVIFYFFR, which binds to the autophosphorylation site of JAK2, resulting in inhibition of its autophosphorylation as well as its phosphorylation of IFNGR subunit IFNGR-1 (14). The JAK2 tyrosine kinase inhibitor peptide (Tkip) did not bind to or inhibit tyrosine phosphorylation of vascular endothelial growth factor receptor or phosphorylation of a substitute peptide by the protooncogene tyrosine kinase c-Src. Tkip, as with SOCS-1, also inhibited EGFR autophosphorylation. It has been suggested that SOCS-1 specifically recognizes the autophosphorylation sequence 1001–1013 containing the phosphotyrosine residue (pY1007) in the activation loop of JAK2 and that the phosphorylation of Y1007 is required for activation (15). SOCS-1 binding blocks JAK2 tyrosine phosphorylation of substrate. Tkip recognizes both unphosphorylated and phosphorylated (p)Y1007, though with higher affinity for pY1007. Thus, Tkip recognizes the JAK2 autophosphorylation site similar to SOCS-1. Tkip has also been shown to inhibit proliferation of prostate cancer cells, blocking JAK2 phosphorylation and activation of the oncogene STAT3 (16). Furthermore, Tkip has been shown to protect mice from experimental allergic encephalomyelitis (EAE), an animal model for multiple sclerosis, via blockage of JAK2 activation of inflammatory cytokines (17). Hence, Tkip appears to have both anti-inflammatory and antitumor properties.

It has been suggested that the binding of SOCS-1 to JAK2 requires the SOCS-1 Src homology 2 (SH2) domain and that the kinase inhibitory region (KIR), while not required for the binding, is essential for the inhibitory action of SOCS-1 (15). We show here that a peptide corresponding to SOCS-1 KIR, SOCS1-KIR peptide, specifically binds to a peptide representing the JAK2 autophosphorylation site and inhibits STAT1 activation. Furthermore, we show that SOCS1-KIR, as well as Tkip, inhibit IFN--induced macrophage activation. We also present data on a novel SOCS-1 antagonist peptide, pJAK2(1001–1013), that enhances suboptimal IFN--induced antiviral activity, enhances IFN--activated sequences (GAS) promoter activity, inhibits SOCS-1 suppression of STAT3 activation of LNCaP prostate cancer cells, and enhances Ag-specific splenocytes proliferation.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Cell culture and virus

Cell lines, except Sf9 cells, were obtained from American Type Culture Collection. The human prostate cancer cells, LNCaP, and the murine macrophage cells, Raw 264.7, were maintained in RPMI 1640 medium (SAFC Biosciences) supplemented with 10% FBS (HyClone), 100 U/ml penicillin and 100 U/ml streptomycin (complete medium). Murine fibroblast cells, L929, were maintained in DMEM (SAFC Biosciences) medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 U/ml streptomycin. The murine monocytes, U937, were maintained in RPMI 1640 complete medium supplemented with 10 mM HEPES (Sigma-Aldrich) and 1 mM sodium pyruvate (Sigma-Aldrich). All these cell types were cultured at 37°C and 5% CO₂ atmosphere. Sf9 insect cells were purchased from Invitrogen Life Technologies and were maintained as adherent cultures in TNM-FH medium or as suspension cultures in Sf-900 II SFM medium (Invitrogen Life Technologies) at 27°C.

Peptides

The peptides used in this study are listed in Table I and were synthesized in our laboratory on an Applied Biosystems 9050 automated peptide synthesizer using conventional fluorenylmethyoxycarbonyl chemistry as described previously (18). A lipophilic (lipo) group (palmitoyl-lysine) was added to the N terminus of peptides to facilitate entry into cells as a last step using a semiautomated protocol. Peptides were characterized by mass spectrometry and purified by HPLC. Peptides were dissolved in water or in DMSO (Sigma-Aldrich).

Binding assays were performed as previously described (14) with minor modifications. Tkip, SOCS1-KIR, and control peptides were bound to 96-well plates, in binding buffer (in 0.1 M carbonate-bicarbonate (pH 9.6)), at a final concentration of 3 µg/well. Wells were then washed in wash buffer (PBS containing 0.9% NaCl and 0.05% Tween 20), blocked with 2% gelatin and 0.05% Tween 20 in PBS for 1 h at room temperature, washed three times with wash buffer, and incubated with various concentrations of biotinylated JAK2(1001–1013) or biotinylated pJAK2(1001–1013) for 1 h at room temperature in blocking buffer. Following incubation, wells were washed five times to remove unbound biotinylated peptide. Bound biotinylated peptides were detected by incubation with 1/500 dilution of neutravidin biotin-binding protein conjugated with HRP (Molecular Probes) in blocking buffer for 1 h at room temperature. Wells were then washed five times with wash buffer and incubated with a solution of o-phenylenediamine in stable peroxidase buffer (Pierce) and color was allowed to develop. The chromogenic reaction was stopped with the addition of 2 M H₂SO₄ (50 µl) to each well. Absorbance was measured using a 450-microplate reader (Bio-Rad) at 490 nm. Control experiments were conducted as described above but in the presence of control peptides.

Peptide competition assays were conducted as described above except following peptide immobilization, washing and blocking, biotinylated JAK2(1001–1013) or biotinylated pJAK2(1001–1013), which had been preincubated (for 1 h at room temperature) with various concentrations of soluble peptide competitors (Tkip, SOCS1-KIR, or control peptide), was added. Detection of bound biotinylated peptide was conducted as described above. Data obtained from binding assays were plotted using GraphPad Prism 4.0 software.

In vitro kinase assays

Autophosphorylation activity of JAK2 was measured in a reaction mixture containing GST-JAK2 kinase fusion protein (Cell Signaling Technology), ATP (20 µM; Cell Signaling Technology), and the appropriate peptide in kinase buffer (10 mM HEPES (pH 7.4), 50 mM sodium chloride, 0.1 mM sodium orthovanadate, 5 mM magnesium chloride, and 5 mM manganese chloride). It had been determined previously that soluble IFNGR-1 enhanced JAK2 activity (14). Hence, IFNGR1 at 2 µg/reaction was added followed by incubation at 25°C for 30 min with intermittent agitation. The reactions were terminated by addition of appropriate volume of 6x SDS-PAGE loading buffer (0.5 M Tris-HCl (pH 6.8), 36% glycerol, 10% SDS, 9.3% DTT, and 0.012% bromphenol blue) and incubation at 95°C for 5 min. The proteins were separated on a 12% SDS-polyacrylamide gel (Bio-Rad), transferred onto a nitrocellulose membrane (Amersham Biosciences), and probed with anti-pJAK2 Abs (Santa Cruz Biotechnology). Membranes were stripped and reprobed with anti-JAK2 Ab (Santa Cruz Biotechnology). Detection of proteins was accomplished using ECL protein detection reagents (Amersham Biosciences).

Autophosphorylation activity of EGFR (Upstate Biotechnology) was measured in a 50-µl reaction containing kinase buffer, 0.2 µg of EGFR (Upstate Biotechnology), 0.1 µg of EGF (Upstate Biotechnology), 10 nM ATP (cell Signaling), and the appropriate peptide (50 µM). The reaction mix was incubated for 30 min at 25°C followed by resolution by 12% SDS-PAGE, transfer onto nitrocellulose membrane, and immunoblotting with anti-pEGFR Ab (Santa Cruz Biotechnology). The membranes were then stripped and reprobed with anti-EGFR Ab. Detection of proteins was accomplished using ECL protein detection reagents (Amersham Biosciences).

Immunoblot analysis of STAT1

U937 murine fibroblast cells were plated on 6-well plates at a cell density of 1 x 10⁶ cells/well and after an overnight incubation at 37°C and 5% CO₂; the cells were cultured in complete medium containing varying concentrations of lipo Tkip, lipo SOCS1-KIR, or lipo control peptide for 18 h at 37°C in a 5% CO₂ incubator. To activate the JAK/STAT-signaling pathway, U937 cells were then incubated in the presence or absence of 1000 U/ml IFN- (PBL Biochemical Laboratories) for an additional 30 min. The medium was aspirated out and the cells washed twice with cold PBS to remove medium and cell debris. Cell lysates were prepared by adding 250 µl of cold lysis buffer (50 mM Tris-HCl (pH 7.4), 250 mM NaCl, 50 mM NaF, 5 mM EDTA, and 0.1% Nonidet P-40) containing protease inhibitor mixture (Amersham Biosciences) and phosphatase inhibitors (Sigma-Aldrich). Lysis was allowed to proceed for 1 h at 4°C (rocking) to ensure complete cell lysis. Lysates were then centrifuged to remove cellular debris and the supernatant was transferred to fresh microcentrifuge tubes. Protein concentrations were determined and protein lysates were resolved by SDS-PAGE on a 12% polyacrylamide gel (Bio-Rad). Proteins were transferred onto nitrocellulose membranes (Amersham Biosciences), nonspecific sites were blocked in blocking buffer (5% nonfat dry milk and 0.1% Tween 20 in TBS), and washed in wash buffer (0.1% Tween 20 in TBS). To detect pSTAT1, membranes were incubated with pY701-STAT1 Ab (1/400 dilution; Santa Cruz Biotechnology) in blocking buffer for 2 h at room temperature. After three washes in wash buffer, the membranes were incubated in HRP-conjugated goat anti-rabbit IgG secondary Ab (1/2000 dilution; Santa Cruz Biotechnology) in blocking buffer for 1 h at room temperature. Following three washes in wash buffer, membranes were incubated for 1 min with ECL detection reagents (Amersham Biosciences) and exposed to photographic film (Amersham Biosciences) to visualize protein bands.

Macrophage activity

Murine macrophage cells, Raw 264.7, were seeded on 24-well plates at a concentration of 3 x 10⁵ cells/well (300 µl/well) and allowed to adhere. Varying concentrations of lipo peptides, Tkip, SOCS1-KIR, or murine IFN- (MuIFN) (95–106), were then added to the wells and the cells incubated for 2 h at 37°C in a 5% CO₂ incubator. Varying concentrations of IFN- were then added and the cells were incubated for an additional 72 h at 37°C in a 5% CO₂ incubator, after which supernatants were transferred to fresh tubes and assayed for nitrite levels as a measure of NO production using Griess reagent, according to the manufacturer’s instructions (Alexis Biochemicals). To test for synergy between Tkip and SOCS1-KIR, the cells were incubated in the presence of IFN- and varying concentrations of peptides as described above and also in the presence of both lipo Tkip and lipo SOCS1-KIR or lipo Tkip and lipo MuIFN (95–106) and were collected after 48 h and tested for NO production as described above.

Ag-specific proliferation assay

SJL/J mice were immunized with bovine myelin basic protein (MBP) as previously described (17), and spleens were extracted and homogenized into a single-cell suspension. Splenocytes (1 x 10⁵ cells/well) were incubated with medium, MBP (50 µg/ml), lipo Tkip, lipo SOCS1-KIR, or lipo MuIFNGR (253–287) for 48 h at 37°C in 5% CO₂. The cultures were pulsed with [³H]thymidine (1.0 µCi/well; Amersham Biosciences) 18 h before harvesting onto filter paper discs using a cell harvester. Cell-associated radioactivity was quantified using a beta scintillation counter, and data are reported as counts per minute.

Antiviral assays for SOCS-1 antagonist function

Antiviral activity was determined using a standard viral cytopathogenic effect assay as described previously with minor modifications (19). Briefly, human fibroblast WISH cells at 70–80% confluency were incubated in medium alone or 0.4 U/ml IFN- (PBL Biomedical Laboratories) or both 0.4 U/ml IFN- and lipo pJAK2(1001–1013) or lipo JAK2(1001–1013) for 22 h in maintenance medium. Following incubation, WISH cells were washed once with maintenance medium and infected with encephalomyocarditis virus (EMCV) (200 PFU/well) for 1 h at 37°C. The WISH cells were then washed once to remove unbound viral particles and incubated in fresh maintenance medium for an additional 24 h at 37°C in a 5% CO₂ incubator. Plates were subsequently blotted dry and stained with 0.1% crystal violet solution for 5 min. Unbound crystal violet was aspirated and the plates were thoroughly rinsed with deionized water, blotted, and air-dried. Viral plaques were counted using a dissecting microscope and percentages of cell survival were determined by comparing experimental treatment groups with the virus-only control group.

Transfection of mammalian cells with SOCS-1 DNA

Transfections were conducted to introduce SOCS-1 DNA into mammalian cells and test the ability of pJAK2 peptide to reverse SOCS-1 inhibition of STAT3 phosphorylation. Human prostate cancer cells, LNCaP, were plated in a 6-well plate and allowed to grow to 60% confluency. SOCS-1 plasmid DNA (1.6 µg/well) (pEF-FLAG-I/mSOCS1), a gift from Dr. D. Hilton (Walter and Eliza Hall Institute of Medical Research, Victoria, Australia; Ref. 7) or an empty vector, was transfected into the LNCaP cells using LipofectAMINE (Invitrogen Life Technologies) and incubated for 4 h, after which the transfection medium was aspirated and fresh complete medium (Eagle’s MEM supplemented with 10% FBS and 100 U/ml streptomycin and 100 U/ml penicillin) added and the cells were incubated for 72 h at 37°C. The complete medium was then aspirated, and fresh medium containing lipo pJAK2(1001–1013) (20 µM) or control peptide (lipo MuIFN (95–125)) was added to the transfected cells, and the JAK/STAT-signaling pathway was activated by adding IL-6 (50 ng/ml). Cells were incubated for 30 min before harvesting. Cell extracts were resolved by SDS-PAGE on a 12% polyacrylamide gel, transferred to a nitrocellulose membrane (Amersham Biosciences), and probed with phosphorylated (pY701) STAT3 Ab (Santa Cruz Biotechnology). The membranes were stripped and reprobed with unphosphorylated STAT3 Ab (Santa Cruz Biotechnology). Detection of proteins was accomplished using ECL detection reagents (Amersham Biosciences).

For immunoprecipitations, LNCaP cells growing on 60-mm plates and at 50% confluency were transfected with either SOCS-1 plasmid DNA (8 µg/plate) or empty vector (8 µg/plate) in LipofectAMINE and incubated for 4 h, after which 5 ml of complete medium was added and cells were allowed to grow for 72 h. The cells extracts were prepared as described for Western blot analysis and incubated with 2 µg/ml anti-FLAG Ab (Sigma-Aldrich) for 2 h at 4°C followed by incubation with Protein G PLUS-agarose beads (Santa Cruz Biotechnology) for an additional 2 h at 4°C. Following centrifugation to pellet protein G immune complexes, supernatants were discarded, immune complexes were washed three times with lysis buffer and once with PBS. The immune complexes were heated (95°C/5 min) in 50 µl of 1x SDS sample buffer, resolved on a 12% polyacrylamide gel, transferred onto nitrocellulose, and immunoblotted with anti-SOCS-1 Ab (Santa Cruz Biotechnology). Detection of proteins was accomplished using ECL detection reagents (Amersham Biosciences).

IFN--activated sequence (GAS) promoter activity

A plasmid, pGAS-Luc, that contains the promoter for GAS linked to the firefly luciferase gene was obtained from Stratagene. A constitutively expressed thymidine kinase promoter-driven Renilla luciferase gene (pRL-TK) (Promega) was used as internal control in reporter gene transfections. WISH cells (1 x 10⁵ cells/well) were seeded in a 12-well plate and incubated overnight at 37°C, following which 3 µg of GAS promoter-driven firefly luciferase expressing plasmid DNA and 10 ng of pRL-TK were cotransfected, into the WISH cells, using Fugene 6 (Roche Diagnostics). Two days later, the cell lysates were used to assay for firefly luciferase and Renilla luciferase, using a dual luciferase assay kit (Promega). Luciferase activity, in relative luciferase units, was calculated by dividing firefly luciferase activity by Renilla luciferase activity in each sample.

Expression of SOCS-1 protein in Sf9 insect cells

Murine SOCS-1 DNA was PCR amplified from the SOCS-1 expression vector, pEF-FLAG-I/mSOCS-1, a gift from Dr. D. Hilton. The PCR products were purified and cloned into the pBlueBac4.5/V5-His TOPO TA expression vector (Invitrogen Life Technologies) and the recombinant vector was used to transform TOP10 chemically competent cells according to the manufacturer’s instructions (Invitrogen Life Technologies). Positive clones were identified by PCR, plasmid DNA was isolated, and the presence of SOCS-1 DNA was confirmed by restriction enzyme digestion and sequencing. The recombinant vector, pBlueBac4.5/His-V5 TOPO, carrying the murine SOCS-1 gene (pBlueBac4.5-His/muSOCS-1), and Bac-N-Blue vector were then cotransfected into Sf9 insect cells (Invitrogen Life Technologies) according to the manufacturer’s instructions. Positive viral constructs, identified by color selection and PCR, were propagated in Sf9 cells to give high titer virus, which were then used to infect 250 ml of Sf9 cells growing in suspension culture. Four days after infection, the Sf9 cells were harvested and protein was extracted using native conditions as described in the Invitrogen Life Technologies instruction manual. Control reactions were conducted similar to SOCS-1 expression except empty vectors were used. Cell lysates were resolved by SDS-PAGE, transferred onto nitrocellulose membrane, and immunoblotted with anti-SOCS-1 Ab. Lysates were also used for competition for binding assays, which were conducted as described previously.

	Results

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Both Tkip and SOCS1-KIR bind to the JAK2 autophosphorylation site

We first determined whether SOCS1-KIR, like the SOCS-1 mimetic Tkip, binds to the JAK2 autophosphorylation site by carrying out dose-response solid-phase binding assays with the JAK2 autophosphorylation site peptide, JAK2(1001–1013). Tkip, SOCS1-KIR, or a control peptide, MuIFN (95–106), were immobilized on 96-well microtiter plates and incubated with biotinylated JAK2(1001–1013) at various concentrations. Tkip and SOCS1-KIR, but not the control peptide, bound to the JAK2(1001–1013) peptide in a dose-dependent manner (Fig. 1A). Thus, both Tkip and SOCS1-KIR specifically bind to the JAK2 autophosphorylation site peptide. Although this is consistent with the SOCS-1 mimetic character of Tkip, it also provides direct evidence that the SOCS1-KIR region of SOCS-1 can interact directly with the JAK2 autophosphorylation site.

View larger version (15K): [in this window] [in a new window]   FIGURE 1. JAK2 autophosphorylation site peptides JAK2(1001–1013) and pJAK2(1001–1013) bind to SOCS1-KIR. A, JAK2(1001–1013) peptide binds to both SOCS1-KIR and Tkip. Biotinylated JAK2(1001–1013), at the indicated concentrations, was added in triplicate to a 96-well plate coated with either Tkip, SOCS-KIR, control peptide (MuIFN (95–106)), or buffer alone. The assays were developed using standard ELISA methods with neutravidin-HRP conjugate to detect bound JAK2(1001–1013). Nonspecific binding was determined from wells that were coated with binding buffer alone, to which biotinylated JAK2(1001–1013) was added. B, Biotinylated pJAK2(1001–1013) binds to both SOCS1-KIR and Tkip. Biotinylated pJAK2(1001–1013) was added to wells coated with either Tkip, SOCS1-KIR, MuIFN (95–106), or buffer and binding assays were conducted as described above. The binding of JAK2(1001–1013) and pJAK2(1001–1013) to Tkip or to SOCS1-KIR when compared with control peptide was statistically significant as determined by two-way ANOVA (p < 0.0001).

To determine whether Tkip and SOCS1-KIR bind to the same site on the JAK2 autophosphorylation site, binding competition assays were conducted. Tkip or SOCS1-KIR was immobilized on a 96-well plate and biotinylated JAK2(1001–1013) or biotinylated pJAK2(1001–1013), which had been preincubated with Tkip, SOCS1-KIR, or a control peptide, was allowed to bind to the immobilized peptides. As shown in Fig. 2A, soluble Tkip and soluble SOCS1-KIR, but not soluble control peptide, inhibited the binding of biotinylated JAK2(1001–1013) to immobilized Tkip. A similar pattern of inhibition was observed with biotinylated JAK2(1001–1013) binding to immobilized SOCS1-KIR (Fig. 2B). Homologous inhibition was slightly better for both Tkip and SOCS1-KIR, which suggests slight differences in recognition of the JAK2 autophosphorylation site.

View larger version (11K): [in this window] [in a new window]   FIGURE 2. Both soluble SOCS1-KIR and soluble Tkip inhibit the binding of biotinylated JAK2(1001–1013) and biotinylated pJAK2(1001–1013) to immobilized Tkip or SOCS1-KIR. A, SOCS1-KIR and Tkip inhibit the binding of JAK2(1001–1013) to immobilized Tkip. Biotinylated JAK2(1001–1013) (500 µM), which had been preincubated with varying concentrations of soluble peptide competitors Tkip, SOCS1-KIR, or control peptide, was added in triplicate to a 96-well plate coated with Tkip. Bound biotinylated JAK2(1001–1013) was detected by ELISA using a neutravidin-HRP conjugate as described in the Materials and Methods. B, SOCS1-KIR and Tkip inhibit the binding of JAK2(1001–1013) to immobilized peptide. Biotinylated JAK2(1001–1013) (500 µM), which had been preincubated with varying concentrations of soluble peptide competitors Tkip, SOCS1-KIR, or control peptide, was added in triplicate to a 96-well plate coated with SOCS1-KIR. Bound biotinylated JAK2(1001–1013) was detected by ELISA using neutravidin-HRP conjugate as described in Materials and Methods. C, SOCS1-KIR and Tkip inhibit the binding of pJAK2(1001–1013) to immobilized Tkip. Biotinylated pJAK2(1001–1013) (500 µM), which had been preincubated with varying concentrations of soluble peptide competitors Tkip, SOCS1-KIR, or control peptide was added in triplicate to a 96-well plate coated with Tkip. Bound biotinylated pJAK2(1001–1013) was detected by ELISA. D, SOCS1-KIR and Tkip inhibit the binding of pJAK2(1001–1013) to immobilized SOCS1-KIR. Biotinylated pJAK2(1001–1013) (500 µM), which had been preincubated with varying concentrations of soluble peptide competitors Tkip, SOCS1-KIR, or control peptide, was added and tested for inhibition of binding. Bound biotinylated pJAK2(1001–1013) was detected by ELISA. For all competition for binding assays, the differences in inhibition of binding by Tkip or SOCS1-KIR, when compared with the control peptide, were statistically significant as determined using two-way ANOVA (p < 0.0001). All experiments were conducted in triplicate and the data are representative of three independent experiments.

JAK2 kinase activity and STAT1 activation

SOCS-1 regulates JAK2 activity at least at two levels. One involves interaction with the autophosphorylation site, which affects JAK2 phosphorylation of substrates such as STAT1 and STAT3 (15). The other level involves induction of proteosomal degradation of both JAK2 and SOCS-1, requiring the SOCS box domain of SOCS-1 (20). Obviously, neither Tkip nor SOCS-KIR has a SOCS box, so we compared the two peptides for their relative ability to inhibit JAK2 autophosphorylation as well as phosphorylation of the transcription factor, STAT1. As shown in Fig. 3A, Tkip but not SOCS1-KIR inhibited JAK2 autophosphorylation. This would suggest that the similar but slight differences in recognition of JAK2 resulted in significant differences in regulation of JAK2 autophosphorylation.

View larger version (22K): [in this window] [in a new window]   FIGURE 3. Differences in kinase inhibition patterns of SOCS1-KIR and Tkip in JAK2 autophosphorylation, STAT1, and EGFR phosphorylation. A, Tkip, but not SOCS1-KIR, inhibits JAK2 autophosphorylation. Tkip, SOCS1-KIR, or control peptide MuIFN (95–106) (50 or 100 µM) was added to in vitro kinase assays, measuring JAK2 autophosphorylation in the presence of IFNGR1 and ATP. The kinase reactions were subjected to SDS-PAGE, and the proteins transferred to nitrocellulose membrane and immunoblotted with anti-pJAK2(pY1007/1008) Ab, after which the membranes were stripped and blotted with anti-JAK2 Ab. Tkip, but not the control peptide or SOCS1-KIR, inhibited JAK2 autophosphorylation. B, SOCS1-KIR and Tkip inhibit IFN--induced STAT1 activation in U937 cells. U937 cells were seeded into 6-well plates at 1 x 106 cells/well and pretreated with medium alone, lipo Tkip, lipo SOCS1-KIR, or lipo control peptide MuIFNGR1 (253–287) for 18 h at 37°C. Following 30-min incubation in the presence or absence of IFN- (1000 U/ml), the cells were washed, harvested, and lysed. Whole cell extracts were resolved on 12% SDS-PAGE, transferred to nitrocellulose membrane, and examined using Abs to pSTAT1 (pY701, upper panel), with the densitometry readings of band intensity shown. The membrane was stripped and reprobed with STAT1 Ab (lower panel). C, Both Tkip and SOCS1-KIR inhibit EGFR phosphorylation. In vitro kinase assays were conducted in which SOCS1-KIR, Tkip, or control peptide was incubated with EGF and EGFR and ATP for 30 min at 25°C. The kinase reaction mixtures were resolved on 12% SDS-PAGE, transferred onto nitrocellulose membrane, and immunoblotted with anti-phosphorylated EGFR Ab (upper panel), with the densitometry readings of band intensities shown. The membrane was stripped and reprobed with STAT1 Ab (lower panel). Both Tkip and SOCS1-KIR inhibited EGFR phosphorylation.

Tkip and SOCS1-KIR inhibit IFN--induced activation of macrophages

IFN- plays an important role in activation of macrophages for innate host defense against intracellular pathogens as well as serving to bridge the link between innate and adaptive immune responses (reviewed in Ref. 21). Thus, Tkip and SOCS1-KIR were examined for their ability to block IFN- activation of the macrophage cell line Raw 264.7 as determined by inhibition of NO production using Griess reagent (Alexis Biochemicals). Lipo versions of the peptides were synthesized with palmitic acid for penetration of the cell membrane (22). Both Tkip and SOCS-KIR, compared with control peptide, inhibited induction of NO by various concentrations of IFN- as shown in Fig. 4A. Dose response with varying concentrations of the peptides against IFN- (6 U/ml) resulted in increased inhibition of NO production by Tkip and SOCS1-KIR with Tkip being the more effective of the inhibitors as shown in Fig. 4B. Control peptide was relatively ineffective at inhibition, providing evidence for the specificity of Tkip and SOCS1-KIR inhibition. Tkip and SOCS1-KIR in combination (33 µM each) were the most effective in inhibition of IFN- induction of NO in macrophages. This synergy may reflect differences in recognition of the autophosphorylation site of JAK2 by the two peptides. Thus, Tkip and SOCS1-KIR both inhibited IFN- induction of NO in macrophages with Tkip being the more effective inhibitor.

View larger version (16K): [in this window] [in a new window]   FIGURE 4. SOCS1-KIR and Tkip inhibit IFN--induced macrophage activation. A, Inhibition of IFN--induced NO production in macrophages. Murine macrophage cells, Raw 264.7, were incubated with varying concentrations of IFN- alone or in the presence of either lipo Tkip, lipo SOCS1-KIR, or lipo control peptide MuIFN (95–106), all at 15 µM final concentration, for 72 h at 37°C and 5% CO2 atmosphere. Culture supernatants were collected and nitrite concentration determined using Griess reagent. SOCS1-KIR and Tkip, but not the control peptide, significantly inhibited IFN--induced nitrite production. The inhibition of macrophage activation by Tkip and SOCS1-KIR compared with control peptide was statistically significant as determined by two-way ANOVA (p < 0.0001). B, Dose-response inhibition of induction of NO and synergy between Tkip and SOCS-KIR. Raw 264.7 cells were treated with IFN- (6 U/ml) alone or in the presence of varying concentrations of Tkip, SOCS1-KIR, or control peptide (MuIFN (253–287)) and assayed for NO production as described above. The differences between Tkip and SOCS1-KIR compared with the control peptide are statistically significant as determined by two-way ANOVA (p < 0.0001). To show synergy, Raw 264.7 cells were treated with IFN- in the presence of varying concentrations of Tkip and SOCS1-KIR and screened for NO production as described above.

We have previously shown that Tkip inhibits Ag-specific proliferation of mouse splenocytes in vitro (23). Specifically, Tkip inhibited proliferation of splenocytes from mice immunized with bovine MBP. In this study, we compared Tkip and SOCS1-KIR for their relative ability to inhibit proliferation of MBP-specific splenocytes in cell culture. Splenocytes (3 x 10⁵ cells/well) were incubated with MBP (50 µg/ml) in the presence of lipo Tkip, lipo SOCS1-KIR, or lipo control peptide for 48 h and proliferation was assessed by testing for [³H]thymidine incorporation. As shown in Fig. 5, both Tkip and SOCS1-KIR inhibited MBP-induced proliferation of splenocytes, while the control peptide had a negligible effect on proliferation. Similar to inhibition of NO production by macrophages, Tkip was more effective than SOCS1-KIR in inhibition of MBP-induced splenocyte proliferation with 84, 88, and 97% inhibition at 1.2, 3.7, and 11 µM, respectively, compared with 61, 67, and 72% for SOCS1-KIR. Thus, both Tkip and SOCS1-KIR inhibited Ag-induced splenocyte proliferation, which is consistent with SOCS-1 protein inhibition of Ag-specific lymphocyte activity (24).

View larger version (16K): [in this window] [in a new window]   FIGURE 5. Both SOCS1-KIR and Tkip inhibit proliferation of murine splenocytes. Splenocytes (1 x 105 cells/well) were obtained from MBP-sensitized SJL/J mice that had developed EAE and were in remission. The splenocytes were incubated with RPMI 1640 medium containing MBP (50 µg/ml) and varying concentrations of lipo SOCS1-KIR, lipo Tkip, or lipo control peptide MuIFNGR1 (253–287) for 48 h. Cultures were then incubated with [3H]thymidine for 18 h before harvesting. Radioactivity was counted on a liquid scintillation counter and data reported as counts per minute above background (medium only). Both lipo SOCS1-KIR and lipo Tkip, but not the control peptide, inhibited splenocyte proliferation in a dose-dependent manner. The inhibition of proliferation by lipo SOCS1-KIR and lipo Tkip, compared with the control peptide, was statistically significant as determined by two-way ANOVA (p < 0.0003). The data are representative of two independent experiments, each conducted in triplicate.

Based in part on binding experiments with truncations of SOCS-1 protein, it has been proposed that the SH2 domain plus ESS binds to JAK2 at the activation site represented by peptide pJAK2(1001–1013), whereas KIR binds primarily to the catalytic site of JAK2 (15). Therefore, we synthesized the ESS peptide, ⁶⁸ITRASALLDACG, and compared it with SOCS1-KIR for binding to biotinylated pJAK2(1001–1013). As shown in Fig. 6, SOCS1-KIR as well as Tkip bound biotin-pJAK2(1001–1013) in a dose-response manner, while ESS failed to bind. Our SOCS1-KIR sequence, except for residues 53–55, is contained in the SOCS-1 ESS-SH2 construct (dN56) in the binding experiment of SOCS-1 (15). Thus, KIR, which is N-terminal and contiguous with ESS, probably shares overlapping functional sites with ESS. Clearly, SOCS1-KIR is preferentially recognized by JAK2(1001–1013) compared with the 12-mer ESS. The specific role of the various residues in the SH2 domain of SOCS-1 in JAK2 and pJAK2(1001–1013) binding remains to be determined.

View larger version (12K): [in this window] [in a new window]   FIGURE 6. Biotinylated pJAK2(1001–1013) binds to SOCS1-KIR but not to a peptide corresponding to the 12-residue ESS peptide (SOCS1-ESS). Biotinylated pJAK2(1001–1013) was added to wells coated with either Tkip, SOCS1-KIR, SOCS1-ESS, MuIFN (95–106), or buffer, and binding assays were conducted as described in Fig. 1. The binding of pJAK2(1001–1013) to SOCS1-KIR when compared with control peptide was statistically significant as determined by two-way ANOVA (p < 0.0001), whereas no significant binding was observed for SOCS1-ESS.

The demonstration above that the KIR of SOCS-1 can bind to the autophosphorylated JAK2 peptide raised the possibility that the phosphorylated peptide, pJAK2(1001–1013), can inhibit the function of endogenous SOCS-1 and thus enhance IFN- and IL-6 activities that are mediated by JAK2 (reviewed in Refs. 25 and 26). As shown in Fig. 7A, the antiviral activity of a suboptimal dose of IFN- (0.4 U/ml) was enhanced against encephalomyocarditis virus (EMCV) in WISH cells by pJAK2(1001–1013). Specifically, unphosphorylated JAK2(1001–1013) at 11 µM final concentration reduced EMCV plaques relative to IFN- alone by 42%, whereas the same concentration of pJAK2(1001–1013) reduced plaques by 59%. This is consistent with better binding of pJAK2(1001–1013) by SOCS1-KIR as shown above and by previous studies showing that SOCS-1 is active against JAK2 phosphorylated at Tyr¹⁰⁰⁷ (15). The peptide alone had no effect on EMCV, similar to medium (data not shown). Thus, pJAK2(1001–1013) boosts the activity of a suboptimal concentration of IFN-, possibly interfering with endogenous SOCS-1 activity.

View larger version (31K): [in this window] [in a new window]   FIGURE 7. pJAK2(1001–1013) peptide has SOCS-1 antagonist properties. A, pJAK2(1001–1013) enhances suboptimal IFN--induced antiviral activity against EMCV in tissue culture. Human fibroblast WISH cells, seeded to confluency in a 24-well plate, were pretreated with human IFN- (0.4 U/ml) and 11 µM pJAK2(1001–1013) or 11 µM JAK2(1001–1013) and incubated for 22 h, after which cells were challenged with EMCV (200 PFU/well) for 1 h. The virus was then removed, and medium was added. Cells were incubated for at least 24 h and then stained with 0.1% crystal violet solution. Unbound crystal violet was aspirated and plates were rinsed thoroughly with deionized water, blotted dry, and air-dried. Viral plaques were counted on a dissecting microscope. B, pJAK2(1001–1013) reverses SOCS-1 inhibition of STAT3 phosphorylation. Human prostate cancer (LNCaP) cells were plated on a 6-well plate and allowed to grow to 60% confluency. SOCS-1 plasmid DNA (8 µg/well) (pEF-FLAG-I/mSOCS1), provided by Dr. D. Hilton, or empty vector was transfected into the LNCaP cells, using LipofectAMINE. Lipo pJAK2(1001–1013) (20 µM) or an equivalent volume of medium was added to the transfected cells, and the JAK/STAT-signaling pathway was activated by adding IL-6 (50 ng/ml). Cells were incubated for 30 min before harvesting. Cell extracts were resolved on 12% SDS-PAGE, transferred to nitrocellulose membrane, and examined using Abs to pSTAT3 (pY705) (upper panel), and the densitometry readings of band intensities are shown. The membranes were stripped and reprobed with unphosphorylated STAT3 Ab (middle panel). SOCS-1 expression in LNCaP cells is shown in the lower panel. The data are representative of two independent experiments. C, pJAK2(1001–1013) enhances GAS promoter activity. WISH cells were transfected with a vector-expressing firefly luciferase, driven by a GAS promoter, along with a vector expressing Renilla luciferase as a control vector. IFN- (1 U/ml) and lipo pJAK2(1001–1013) at 5 or 1 µM final concentration, or a control peptide, MuIFN (95–125) (5 µM), were added to the cells. After 48 h of incubation, the cell extracts were assayed for relative luciferase activities using a luminometer. D, pJAK2(1001–1013) enhances immune response to BSA in C57BL/6 mice. Mice were injected i.p. with 200 µg of lipo pJAK2(1001–1013), control IFN-R (IFNGR1) peptide lipo IFNGR1 (253–287) or PBS on day –2, –1, and 0 relative to i.p. injection of 50 µg of BSA. Four weeks later, spleens were removed, and separated cells (5 x 105) were stimulated in 96-well plates with 0.5 µg of BSA for 96 h. Tritiated thymidine was added 18 h before harvesting. Triplicates were counted for incorporation of radioactivity and data were represented as cpm.

We next determined whether pJAK2(1001–1013) could enhance GAS promoter activity of IFN-. Accordingly, a plasmid with the GAS promoter element linked to the firefly luciferase reporter gene was cotransfected along with Renilla luciferase reporter plasmid as a control, into WISH cells. As shown in Fig. 7C, treatment of the WISH cells with IFN- (1 U/ml) resulted in a 4-fold relative increase in luciferase activity, which was increased to 10- and 5-fold by 5 and 1 µM pJAK2(1001–1013), respectively. pJAK2(1001–1013) alone did not activate the reporter gene (data not shown) and control peptide did not enhance IFN- activation of the reporter gene. Thus, consistent with the anti-SOCS-1 effects of pJAK2(1001–1013), the peptide also enhanced IFN- function at the level of gene activation.

It has recently been shown that suppression of SOCS-1 in dendritic cells by small-interfering RNA (siRNA) enhances antitumor immunity (27). Therefore, we treated C56BL/6 mice with lipo pJAK2(1001–1013) and determined its effect on cell-mediated response to BSA. As shown in Fig. 7D, BSA-induced proliferation of splenocytes of mice 4 wk after treatment was enhanced 4- to 5-fold by JAK2 peptide SOCS-1 antagonist when compared with control peptide or PBS-treated mice. Thus, pJAK2(1001–1013) enhanced the immune response similar to siRNA. We have shown here, therefore, that pJAK2(1001–1013) antagonizes SOCS-1 activity at four different levels: IFN- antiviral function, IL-6 signal transduction, IFN- activation of reporter gene via the GAS promoter, and enhancement of Ag-specific proliferation.

SOCS-1 protein competes with SOCS1-KIR for binding to pJAK2(1001–1013)

To directly compare SOCS-1 and SOCS1-KIR for their relative ability to compete for the autophosphorylation peptide pJAK2(1001–1013), Sf9 insect cells were transfected with the SOCS-1 gene via a baculovirus expression vector for production of SOCS-1 protein (Invitrogen Life Technologies). As shown in Fig. 8, soluble SOCS-1 protein specifically competed with SOCS1-KIR for binding to biotinylated pJAK2(1001–1013), suggesting that SOCS1-KIR recognizes pJAK2(1001–1013) similarly to SOCS-1. This does not preclude other sites on SOCS-1 from interacting with the JAK2 autophosphorylation site. Nor does it preclude SOCS1-KIR from interacting with the catalytic site of JAK2 as has been proposed (15). Additionally, the demonstration of SOCS-1 competition for pJAK2(1001–1013) is consistent with pJAK2(1001–1013) antagonism via sequestration of critical functional site(s) on SOCS-1.

View larger version (21K): [in this window] [in a new window]   FIGURE 8. Soluble SOCS-1 protein, similar to SOCS1-KIR, inhibits the binding of biotinylated pJAK2(1001–1013) to SOCS1-KIR. A, Biotinylated pJAK2(1001–1013) (200 µM), which had been preincubated with varying concentrations of soluble SOCS1-KIR, control peptide, SOCS-1 lysate, or control lysate, was added in triplicate to a 96-well plate coated with SOCS1-KIR. Bound biotinylated pJAK2(1001–1013) was detected by ELISA using a neutravidin-HRP conjugate as described in Materials and Methods. SOCS-1 sample inhibition was significant at p < 0.05 compared with control sample for 110 and 330 µg/ml protein as determined by the Wilcoxon/Mann-Whitney rank-sum two-sided test. B, Immunoblot with anti-SOCS1 Ab showing expression of murine SOCS-1 protein in Sf9 insect cells.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

The dynamics of induction of SOCS-1 by IFN- in cells and the activation of STAT1 is illustrative of how SOCS-1 attenuates IFN- functions under physiological conditions. For example, treatment of monocytes or astrocytes with IFN- was followed by activation of the SOCS-1 gene at 90 min (30, 31). Low doses of IFN- resulted in transient increases in SOCS-1 mRNA that returned to baseline after 4 h, whereas high concentrations of IFN- resulted in increases of SOCS-1 mRNA up to 24 h. Thus, the SOCS-1 response appears to be induced by the IFN- signal. Treatment of hepatocytes from SOCS-1^+/+ mice with IFN- resulted in STAT1 activation within 15 min, which peaked by 2 h before declining (31). Although STAT1 is similarly activated in SOCS-1-deficient livers, it persists for 8 h. SOCS-1 thus appears to attenuate IFN--persistent activation of STAT1, which nonetheless allows the beneficial effects of IFN--induced signaling.

Given the critical importance of SOCS-1 in modulating the activities of IFN- and other inflammatory cytokines that use tyrosine kinases such as JAK2 in their signaling pathways, we have developed the small Tkip, which is a mimetic of SOCS-1 (14). Tkip was designed to recognize the autophosphorylation site on JAK2 involving residues 1001–1013 containing the critical tyrosine at 1007 (15). We showed that Tkip blocked JAK2 autophosphorylation as well as tyrosine phosphorylation of substrates such as STAT1 and the IFN-R chain, IFNGR1 (14). As with SOCS-1, Tkip also blocked EGFR autophosphorylation, while not affecting the tyrosine kinase function of c-Src and vascular endothelial growth factor receptor. We subsequently showed that Tkip blocked IL-6-induced activation of the STAT3 oncogene in LNCaP prostate cancer cells, which involved inhibition of JAK2 activation (16). These studies presented a proof-of-concept demonstration of a peptide mimetic of SOCS-1 that regulates JAK2 tyrosine kinase function.

Because of its potential for regulation of inflammatory conditions where tyrosine kinases such as JAK2 play a role in the resultant pathology, we tested Tkip in a mouse model of multiple sclerosis called EAE (17). SJL/J mice were immunized with MBP for induction of the relapsing/remitting form of EAE. Tkip, 63 µg every other day, completely protected the mice against relapses compared with control groups in which >70% of the mice relapsed after primary incidence of disease. Protection of mice correlated with lower MBP Ab titers in Tkip-treated groups as well as suppression of MBP-induced proliferation of splenocytes taken from EAE-afflicted mice. Consistent with its JAK2 inhibition function, Tkip also inhibited the activity of inflammatory cytokine TNF-, which uses the STAT1 transcription factor. Thus, Tkip, as with SOCS-1, possesses anti-inflammatory activity that protects mice against ongoing relapsing/remitting EAE.

Our design of Tkip was independent of any knowledge of the structural and functional domains of SOCS-1. However, given that we focused on Tkip binding to the autophosphorylation site of JAK2, we compared it with regions of SOCS-1 that have been proposed to be either directly involved in such binding or to be involved in enhancement of SOCS-1 binding to the autophosphorylation site. Yasukawa et al. (15) identified three regions that were directly involved in SOCS-1 binding to JAK2, the large SH2 domain, a N-terminal 12-aa sequence called extended SH2 (ESS), and an additional N-terminal 12-aa region called the KIR. The ESS and SH2 domains were felt to bind to the autophosphorylation or activation site of JAK2, while KIR bound to the catalytic site in this model. The 12-aa ESS sequence consists of residues 68–79, whereas our SOCS1-KIR sequence compared with the KIR above consists of residues 53–68, sharing just the I68 with the ESS and containing three additional residues in its N terminus. In comparative binding, our SOCS1-KIR bound to pJAK2(1001–1013), whereas ESS failed to bind (Fig. 6). Close examination of N-terminal truncated SOCS-1-expressed proteins, designated dN51 (missing residues N-terminal to 51) and dN68, showed that removal of the KIR resulted in loss of binding to JAK2 in transfected cells (15). Furthermore, in direct binding to the pJAK2 autophosphorylation site peptide by truncated dN56 SOCS-1 protein, our SOCS1-KIR sequence except for residues 53–55, was present along with ESS and SH2 (15). Although the region of SOCS-1 that binds to the autophosphorylation site of JAK2 as per Yasukawa et al. (15) is referred to as SOCS-1 SH2 plus ESS, the bindings that they refer to also contained our SOCS1-KIR sequence. Additionally, SOCS-1 protein competed with SOCS1-KIR for pJAK2(1001–1013), suggesting that the two recognized the JAK2 autophosphorylation site similarly. Thus, we feel that the binding data with our SOCS1-KIR are consistent with the binding studies of these authors. It should be noted that the peptide-binding approach used here does not involve assessment of collaboration and/or synergism among the KIR, ESS, and the SH2 domains of SOCS-1. Thus, based on the studies reported here, along with those by others (15), KIR, ESS, and SH2 may all be involved in binding to the JAK2 autophosphorylation site. It remains to be determined as to the extent of their relative roles.

We have shown in this study that SOCS1-KIR, independent of other domains of SOCS-1, can bind directly to a peptide, JAK2(1001–1013), that corresponds to the autophosphorylation site of JAK2. Furthermore, we showed that SOCS1-KIR competed with Tkip for binding to JAK2(1001–1013). The competitions suggest that the peptides recognized JAK2 similarly but not exactly the same way. Phosphorylation of Tyr¹⁰⁰⁷ on the JAK2 peptide enhanced binding of Tkip and SOCS1-KIR. Tkip blocked JAK2 autophosphorylation as well as JAK2 phosphorylation of STAT1, while SOCS1-KIR did not block autophosphorylation but did block phosphorylation of STAT1, similar to the pattern or profile of SOCS-1 inhibition of phosphorylation (12). The peptides were also functionally similar in inhibiting IFN- activation of macrophages to produce NO and inhibition of Ag-specific induction of proliferation of splenocytes, with Tkip being the more effective inhibitor. Thus, we have shown here that the KIR region of SOCS-1 can directly bind to the autophosphorylation site of JAK2. We have also further demonstrated the SOCS-1 mimetic property of Tkip at the level of JAK2 recognition.

Tkip is relatively hydrophobic, while SOCS1-KIR is hydrophilic. However, both peptides have hydropathic profiles that are complementary to that of pJAK2(1001–1013). ESS, however, had a hydropathic profile different from Tkip. Tkip was designed to have a hydropathic profile complementary to that of pJAK2(1001–1013) (14, 32). Thus, Tkip would recognize primarily hydrophobic residues or groups in the pJAK2 peptide, while SOCS1-KIR would recognize primarily hydrophilic residues or groups. The binding competition could thus be due to a steric interference, which is consistent with differential effects of Tkip and SOCS1-KIR on JAK2 kinase activity.

The fact that the KIR of SOCS-1 can bind directly to pJAK2(1001–1013) raises the possibility that pJAK2(1001–1013) can function as an antagonist of SOCS-1. We have thus shown here under four different types of experiments that pJAK2(1001–1013) possesses SOCS-1 antagonist properties. First, pJAK2(1001–1013) enhanced suboptimal IFN- activity. Second, prostate cancer cells transfected for constitutive production of SOCS-1 protein had reduced activation of STAT3 by IL-6 treatment. pJAK2(1001–1013) reversed the SOCS-1 effect. Third, pJAK2(1001–1013) enhanced IFN- activation of the luciferase reporter gene via the GAS promoter. Fourth, pJAK2(1001–1013) enhanced Ag-specific splenocyte proliferation. As indicated above, treatment of cells with IFN- resulted in activation of the SOCS-1 gene in 90 min and it has been proposed that it is associated with the physiological attenuation of the IFN- response by SOCS-1 (30, 31). Consistent with this, it has been reported recently that siRNA inhibition of SOCS-1 expression in bone marrow dendritic cells resulted in enhanced CTL activity and IFN- production by ELISPOT, culminating in enhancement of antitumor immunity (27).

We have thus shown here that SOCS1-KIR binds directly to the autophosphorylation site of JAK2, similar to the binding of Tkip SOCS-1 mimetic, which results in inhibition of JAK2 phosphorylation of substrate. This directly identifies a region of SOCS-1 that possesses intrinsic antikinase function. Related to this, the autophosphorylation site peptide, pJAK2(1001–1013), functioned as an antagonist of SOCS-1. These findings with SOCS-1 mimetics and antagonists have implications for novel therapeutic approaches to mimicking SOCS-1 for treatment of inflammatory diseases and for suppressing SOCS-1 to enhance the immune response against cancer and infectious diseases.

	Disclosures

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The authors have no financial conflict of interest.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by National Institutes of Health Grants NS051245 and AI 056152 (to H.M.J.).

² Current address: Department of Physical Sciences and Mathematics, Florida Gulf Coast University, Fort Myers, FL 33965.

³ Current address: Department of Biology, Fayetteville State University, Fayetteville, NC 28301.

⁴ Address correspondence and reprint requests to Dr. Howard M. Johnson, Department of Microbiology and Cell Science, University of Florida, P.O. Box 110700, Building 981, Room 1052, Gainesville, FL 32611. E-mail address: johnsonh{at}ufl.edu

⁵ Abbreviations used in this paper: IFNGR, IFN- receptor; SOCS, suppressor of cytokine signaling; EGFR, epidermal growth factor receptor; Tkip, tyrosine kinase inhibitor peptide; SH2, Src homology 2; KIR, kinase inhibitory region; lipo, lipophilic; MuIFN, murine IFN-; GAS, IFN--activated sequence; MBP, myelin basic protein; EMCV, encephalomyocarditis virus; p, phosphorylated; ESS, extended SH2 sequence; siRNA, small-interfering RNA; EAE, experimental allergic encephalomyelitis.

Received for publication September 8, 2006. Accepted for publication February 5, 2007.

	References

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 

1. Yamoaka, K., P. Saharinen, M. Pesu, V. E. Holt, III, O. Silvennoinen, J. J. O’Shea. 2004. The Janus kinases. Genome Biol. 5: 253-258. [Medline]
2. Parganas, E., D. Wang, D. J. Stravapodis, D. Topham, J. C. Marine, S. Teglund, E. F. Vanin, S. Bodner, O. Colamonici, J. M. Deursen, et al 1998. JAK2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395. [Medline]
3. Subramaniam, P. S., B. A. Torres, H. M. Johnson. 2001. So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors. Cytokine 15: 175-187. [Medline]
4. Johnson, H. M., P. S. Subramaniam, S. Olsnes, D. A. Jans. 2004. Trafficking and signaling pathways of molecular localizing protein ligands and their receptors. BioEssays 26: 993-1004. [Medline]
5. Kotenko, S. V., S. Pestka. 2000. JAK-STAT signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19: 2557-2567. [Medline]
6. Bromberg, J., J. E. Darnell, Jr. 2000. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473. [Medline]
7. Starr, R., T. A. Willson, E. M. Viney, L. J. L. Murray, J. R. Rayner, B. J. Jenkins, T. J. Gonda, W. S. Alexander, D. Metcalf, N. A. Nicola, D. J. Hilton. 1997. A family of cytokine-inducible inhibitors of signaling. Nature 387: 917-921. [Medline]
8. Endo, T. A., M. Masuhara, M. Yokouchi, R. Suzuki, H. Sakamoto, K. Mitsui, A. Matsumoto, S. Tanimura, M. Ohtsubo, H. Misakawa, et al 1997. A new protein containing SH2 domain that inhibits JAK kinases. Nature 387: 921-924. [Medline]
9. Naka, T., M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Anono, N. Nashimoto, T. Kajita, T. Taga, K. Yoshizaki, et al 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924-929. [Medline]
10. Alexander, W. S.. 2002. Suppressors of cytokine signaling (SOCS) in the immune system. Nat. Rev. Immunol. 2: 410-416. [Medline]
11. Larsen, L., C. Röpke. 2002. Suppressors of cytokine signaling: SOCS. APMIS 110: 833-844. [Medline]
12. Alexander, W. S., D. J. Hilton. 2004. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of immune responses. Annu. Rev. Immunol. 22: 503-529. [Medline]
13. Calo, V., M. Migliavacca, V. Bazan, M. Macaluso, M. Busemi, N. Gebba, A. Russo. 2003. STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. 197: 157-168. [Medline]
14. Flowers, L. O., H. M. Johnson, M. G. Mujtaba, M. R. Ellis, S. M. Haider, P. S. Subramaniam. 2004. Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function. J. Immunol. 172: 7510-7518. [Abstract/Free Full Text]
15. Yasukawa, H., H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, T. Wakioka, S. Ohtsuka, T. Imaizumi, T. Matsuda, J. N. Ihle, A. Yoshimura. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18: 1309-1320. [Medline]
16. Flowers, L. O., P. S. Subramaniam, H. M. Johnson. 2005. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 24: 2114-2120. [Medline]
17. Mujtaba, M. G., L. O. Flowers, C. B. Patel, R. A. Patel, M. I. Haider, H. M. Johnson. 2005. Treatment of mice with the suppressor of cytokine signaling-1 peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing/remitting form. J. Immunol. 175: 5077-5086. [Abstract/Free Full Text]
18. Szente, B. E., I. J. Weiner, M. J. Jablonsky, N. R. Krishna, B. A. Torres, H. M. Johnson. 1996. Structural requirements for agonist activity of a murine interferon peptide. J. Interferon Cytokine Res. 16: 813-817. [Medline]
19. Langford, M. P., D. A. Weiget, G. J. Stanton, S. Baron. 1981. Viral plaque-reduction assay for interferon: microplaque and regular macroplaque reduction assay. Methods Enzymol. 78: 339-349. [Medline]
20. Zhang, J., G. D. Metcalf, S. Rakar, M. Asimakis, C. J. Greenhalgh, T. A. Willson, R. Starr, S. E. Nicholson, W. Carter, W. S. Alexander, et al 2001. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc. Natl. Acad. Sci. USA 98: 13261-13265. [Abstract/Free Full Text]
21. Boehn, U., T. Klamp, M. Groot, J. C. Howar. 1997. Cellular responses to interferon . Annu. Rev. Immunol. 15: 749-795. [Medline]
22. Thiam, K., E. Long, C. Verwaerde, C. Auriault, H. Gras-Masse. 1999. IFN-derived lipopeptide: influence of lipid modification on the conformation and the ability to induce MHC class II expression on murine and human cells. J. Med. Chem. 42: 3732-3736. [Medline]
23. Mujtaba, M. G., C. B. Patel, R. A. Patel, L. O. Flowers, M. A. Burkhat, L. W. Waiboci, J. P. Martin, M. I. Haider, C. M. Ahmed, H. M. Johnson. 2006. The interferon mimetic peptide IFN-(95–133) prevents encephalomyocarditis virus infection both in tissue culture and in mice. Clin. Vaccine Immunol. 13: 944-952. [Abstract/Free Full Text]
24. Cornish, A. L., M. M. Chong, G. M. Davey, R. Darwiche, N. A. Nicola, D. J. Hilton, T. W. Kay, R. Starr, W. S. Alexander. 2003. Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other _c-dependent cytokines in peripheral T cells. J. Biol. Chem. 278: 22755-22761. [Abstract/Free Full Text]
25. Kisseleva, T., S. Bhattacharya, J. Braunstein, C. W. Schindler. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285: 1-25. [Medline]
26. Heinrich, P. C., I. Behrmann, S. Haan, H. M. Hermanns, G. Muller-Newen, F. Schaper. 2003. Principles of interleukin (IL)-6 type cytokine signaling and regulation. Biochem. J. 374: 1-20. [Medline]
27. Shen, L., K. Evel-Kabler, R. Strube, S. Y. Chen. 2004. Silencing SOCS-1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22: 1546-1553. [Medline]
28. Alexander, W. S., R. Starr, J. E. Fenner, C. L. Scott, E. Handman, N. S. Sprigg, J. E. Corbin, A. L. Cornish, R. Darwiche, C. M. Owczarek, et al 1999. SOCS-1 is a critical inhibitor of interferon signaling and prevents potentially fatal neonatal actions of this cytokine. Cell 98: 597-608. [Medline]
29. Yoshimura, A.. 2005. Negative regulation of cytokine signaling. Clin. Rev. Allergy Immunol. 28: 205-220. [Medline]
30. Dickensheets, H. L., C. Venkataraman, U. Schindler, R. P. Donnelly. 1999. Interferon activation of STAT6 by interleukin-4 in human monocytes by induction of SOCS-1 gene expression. Proc. Natl. Acad. Sci. USA 96: 10800-10805. [Abstract/Free Full Text]
31. Brysha, M., J. G. Zhang, P. Bertolino, J. E. Corbin, W. S. Alexander, N. A. Nicola, D. J. Hilton, R. Starr. 2001. Suppressor of cytokine signaling-1 attenuates the duration of interferon signal transduction in vitro and in vivo. J. Biol. Chem. 276: 22086-22089. [Abstract/Free Full Text]
32. Weathington, N. M., J. E. Blalock. 2003. Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network. Expert Rev. Vaccines 2: 61-73. [Medline]

This article has been cited by other articles: